Search research articles
Contact Us
Filters
Showing results (51-60 of 59) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 59 results.
Schizophrenia Research
|
September 3, 2018
Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data
Willie Earley, Hua Guo, David Daniel, et al.
The American Journal of Psychiatry
|
November 7, 2015
An 8-Week Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar I Depression
Suresh Durgam, Willie Earley, Alan Lipschitz, et al.
The American Journal of Psychiatry
|
December 1, 2025
Adjunctive Lumateperone in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial
Suresh Durgam, Willie R Earley, Susan G Kozauer, et al.
Clinical and Translational Science
|
October 31, 2019
Relationship Between Plasma Concentrations and Clinical Effects of Cariprazine in Patients With Schizophrenia or Bipolar Mania
Antonia Periclou, Susan Willavize, David Jaworowicz, et al.
International Clinical Psychopharmacology
|
July 22, 2025
Lumateperone monotherapy for major depressive episodes associated with bipolar disorder: efficacy and safety in a randomized placebo-controlled trial
Christoph U Correll, Suresh Durgam, Susan G Kozauer, et al.
The American Journal of Psychiatry
|
September 23, 2021
Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial
Joseph R Calabrese, Suresh Durgam, Andrew Satlin, et al.
Lancet (London, England)
|
February 11, 2017
Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial
György Németh, István Laszlovszky, Pál Czobor, et al.
Bipolar Disorders
|
February 13, 2023
Adjunctive lumateperone (ITI-007) in the treatment of bipolar depression: Results from a randomized placebo-controlled clinical trial
Trisha Suppes, Suresh Durgam, Susan G Kozauer, et al.
Psychopharmacology
|
August 16, 2016
Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO
Ragy R Girgis, Mark Slifstein, Deepak D'Souza, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 59) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 59 results.
Schizophrenia Research
|
September 3, 2018
Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data
Willie Earley, Hua Guo, David Daniel, et al.
The American Journal of Psychiatry
|
November 7, 2015
An 8-Week Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar I Depression
Suresh Durgam, Willie Earley, Alan Lipschitz, et al.
The American Journal of Psychiatry
|
December 1, 2025
Adjunctive Lumateperone in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial
Suresh Durgam, Willie R Earley, Susan G Kozauer, et al.
Clinical and Translational Science
|
October 31, 2019
Relationship Between Plasma Concentrations and Clinical Effects of Cariprazine in Patients With Schizophrenia or Bipolar Mania
Antonia Periclou, Susan Willavize, David Jaworowicz, et al.
International Clinical Psychopharmacology
|
July 22, 2025
Lumateperone monotherapy for major depressive episodes associated with bipolar disorder: efficacy and safety in a randomized placebo-controlled trial
Christoph U Correll, Suresh Durgam, Susan G Kozauer, et al.
The American Journal of Psychiatry
|
September 23, 2021
Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial
Joseph R Calabrese, Suresh Durgam, Andrew Satlin, et al.
Lancet (London, England)
|
February 11, 2017
Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial
György Németh, István Laszlovszky, Pál Czobor, et al.
Bipolar Disorders
|
February 13, 2023
Adjunctive lumateperone (ITI-007) in the treatment of bipolar depression: Results from a randomized placebo-controlled clinical trial
Trisha Suppes, Suresh Durgam, Susan G Kozauer, et al.
Psychopharmacology
|
August 16, 2016
Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO
Ragy R Girgis, Mark Slifstein, Deepak D'Souza, et al.
Page
of 6